Heron Therapeutics (STU:AXD2) Total Liabilities : €231.5 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Heron Therapeutics Total Liabilities?

Heron Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was €231.5 Mil.

Heron Therapeutics's quarterly Total Liabilities declined from Sep. 2023 (€240.80 Mil) to Dec. 2023 (€235.19 Mil) and declined from Dec. 2023 (€235.19 Mil) to Mar. 2024 (€231.52 Mil).

Heron Therapeutics's annual Total Liabilities increased from Dec. 2021 (€201.90 Mil) to Dec. 2022 (€224.09 Mil) and increased from Dec. 2022 (€224.09 Mil) to Dec. 2023 (€235.19 Mil).

Heron Therapeutics Total Liabilities Historical Data

The historical data trend for Heron Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heron Therapeutics Total Liabilities Chart

Heron Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

98.05

96.23

201.90

224.09

235.19

Heron Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															216.98	221.99	240.80	235.19	231.52

Heron Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Heron Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	73.071	+	(161.899	+	0.221
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	235.2

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	204.038	-	-31.153
	=	235.2

Heron Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	69.348	+	(161.951	+	0.22200000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	231.5

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	200.456	-	-31.065
	=	231.5

Heron Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Heron Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Heron Therapeutics (STU:AXD2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heron Therapeutics Inc (STU:AXD2) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

HRTX:USA AXD2:Germany

Address

4242 Campus Point Court, Suite 200, San Diego, CA, USA, 92121

Website

https://www.herontx.com

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.

Heron Therapeutics (STU:AXD2) Headlines

No Headlines